Tag Archives: CEOs

JPM 2019: Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal

SAN FRANCISCO—Bristol-Myers Squibb and Celgene sent 2019’s first big shockwave throughout pharma with last week’s $ 74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on the patent side and pipeline, too. But even as market watchers continued to offer up their reservations on… Read More »